These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 34965958)

  • 41. Discovery of novel class of histone deacetylase inhibitors as potential anticancer agents.
    El-Awady R; Saleh E; Hamoudi R; Ramadan WS; Mazitschek R; Nael MA; Elokely KM; Abou-Gharbia M; Childers WE; Srinivasulu V; Aloum L; Menon V; Al-Tel TH
    Bioorg Med Chem; 2021 Jul; 42():116251. PubMed ID: 34116381
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Histone deacetylase inhibitors in the treatment for multiple myeloma.
    Hideshima T; Anderson KC
    Int J Hematol; 2013 Mar; 97(3):324-32. PubMed ID: 23475757
    [TBL] [Abstract][Full Text] [Related]  

  • 43. R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies.
    Arts J; Angibaud P; Mariën A; Floren W; Janssens B; King P; van Dun J; Janssen L; Geerts T; Tuman RW; Johnson DL; Andries L; Jung M; Janicot M; van Emelen K
    Br J Cancer; 2007 Nov; 97(10):1344-53. PubMed ID: 18000499
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Developing selective histone deacetylases (HDACs) inhibitors through ebselen and analogs.
    Wang Y; Wallach J; Duane S; Wang Y; Wu J; Wang J; Adejare A; Ma H
    Drug Des Devel Ther; 2017; 11():1369-1382. PubMed ID: 28496307
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A histone deacetylase inhibitor, largazole, decreases liver fibrosis and angiogenesis by inhibiting transforming growth factor-β and vascular endothelial growth factor signalling.
    Liu Y; Wang Z; Wang J; Lam W; Kwong S; Li F; Friedman SL; Zhou S; Ren Q; Xu Z; Wang X; Ji L; Tang S; Zhang H; Lui EL; Ye T
    Liver Int; 2013 Apr; 33(4):504-15. PubMed ID: 23279742
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Class I and class II histone deacetylases are potential therapeutic targets for treating pancreatic cancer.
    Wang G; He J; Zhao J; Yun W; Xie C; Taub JW; Azmi A; Mohammad RM; Dong Y; Kong W; Guo Y; Ge Y
    PLoS One; 2012; 7(12):e52095. PubMed ID: 23251689
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy.
    Singh AK; Bishayee A; Pandey AK
    Nutrients; 2018 Jun; 10(6):. PubMed ID: 29882797
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Protein acetylation in the cardiorenal axis: the promise of histone deacetylase inhibitors.
    Bush EW; McKinsey TA
    Circ Res; 2010 Feb; 106(2):272-84. PubMed ID: 20133912
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Investigation of the effect of different linker chemotypes on the inhibition of histone deacetylases (HDACs).
    Linciano P; Benedetti R; Pinzi L; Russo F; Chianese U; Sorbi C; Altucci L; Rastelli G; Brasili L; Franchini S
    Bioorg Chem; 2021 Jan; 106():104462. PubMed ID: 33213894
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Histone deacetylase inhibitors in cancer treatment.
    Vigushin DM; Coombes RC
    Anticancer Drugs; 2002 Jan; 13(1):1-13. PubMed ID: 11914636
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Development and therapeutic impact of HDAC6-selective inhibitors.
    Dallavalle S; Pisano C; Zunino F
    Biochem Pharmacol; 2012 Sep; 84(6):756-65. PubMed ID: 22728920
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Targeting class I histone deacetylases in cancer therapy.
    Delcuve GP; Khan DH; Davie JR
    Expert Opin Ther Targets; 2013 Jan; 17(1):29-41. PubMed ID: 23062071
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Targeting histone deacetylases: development of vorinostat for the treatment of cancer.
    Richon VM
    Epigenomics; 2010 Jun; 2(3):457-65. PubMed ID: 22121904
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Histone deacetylase inhibitors in hematological malignancies and solid tumors.
    Chun P
    Arch Pharm Res; 2015 Jun; 38(6):933-49. PubMed ID: 25653088
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Therapeutic potential for HDAC inhibitors in the heart.
    McKinsey TA
    Annu Rev Pharmacol Toxicol; 2012; 52():303-19. PubMed ID: 21942627
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Inhibition of histone deacetylases.
    Huang Y; Shaw PG; Davidson NE
    Methods Mol Biol; 2011; 791():297-311. PubMed ID: 21913088
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phenylpyrrole-based HDAC inhibitors: synthesis, molecular modeling and biological studies.
    Brindisi M; Cavella C; Brogi S; Nebbioso A; Senger J; Maramai S; Ciotta A; Iside C; Butini S; Lamponi S; Novellino E; Altucci L; Jung M; Campiani G; Gemma S
    Future Med Chem; 2016 Sep; 8(13):1573-87. PubMed ID: 27556815
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy.
    Ramaiah MJ; Tangutur AD; Manyam RR
    Life Sci; 2021 Jul; 277():119504. PubMed ID: 33872660
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Structure-activity relationship and mechanistic studies for a series of cinnamyl hydroxamate histone deacetylase inhibitors.
    Tavares MT; de Almeida LC; Kronenberger T; Monteiro Ferreira G; Fujii de Divitiis T; Franco Zannini Junqueira Toledo M; Mariko Aymoto Hassimotto N; Agostinho Machado-Neto J; Veras Costa-Lotufo L; Parise-Filho R
    Bioorg Med Chem; 2021 Apr; 35():116085. PubMed ID: 33668008
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents.
    Mottamal M; Zheng S; Huang TL; Wang G
    Molecules; 2015 Mar; 20(3):3898-941. PubMed ID: 25738536
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.